Patents by Inventor Matthias Machacek

Matthias Machacek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20230346926
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: December 2, 2022
    Publication date: November 2, 2023
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20230321231
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20230293683
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: October 21, 2022
    Publication date: September 21, 2023
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • Methods of treating psoriasis using IL-17 antagonists
    Patent number: 11534490
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Methods of treating ankylosing spondylitis using IL-17 antagonists
    Patent number: 11534491
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
    Publication number: 20220193234
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: December 8, 2021
    Publication date: June 23, 2022
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20210177966
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthiritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20210162044
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 3, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20210128726
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: December 18, 2020
    Publication date: May 6, 2021
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20210113688
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20200276305
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: March 19, 2020
    Publication date: September 3, 2020
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20200171147
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 4, 2020
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Methods of treating psoriasis using IL-17 antibodies
    Patent number: 10583190
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 10, 2020
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
    Publication number: 20190307880
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: June 12, 2019
    Publication date: October 10, 2019
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • Methods of treating psoriatic arthritis using IL-17 antagonists
    Patent number: 10363307
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Novartis AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
    Publication number: 20180008706
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: July 20, 2017
    Publication date: January 11, 2018
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20170304439
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 26, 2017
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • COMPOSITIONS AND METHODS FOR LONG ACTING PROTEINS
    Publication number: 20170290876
    Abstract: The present invention is based, in part, on the discovery of peptide tags that increase the half-life and/or mean residence time of proteins or nucleic acids in the eye. In certain aspects the invention peptide tags increase the half-life and/or mean residence time of antibodies and antigen binding fragments, therapeutic proteins, protein receptors, DARPins and/or aptamers in the eye.
    Type: Application
    Filed: June 24, 2015
    Publication date: October 12, 2017
    Applicant: Novartis AG
    Inventors: Joy GHOSH, Michael ROGUSKA, Andrew Anh NGUYEN, Thomas PIETZONKA, Stephen Hedrick POOR, Matthias MACHACEK, Chad Eric BIGELOW
  • Methods of treating ankylosing spondylitis using IL-17 antagonists
    Patent number: 9744234
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., 1L-1 7 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: August 29, 2017
    Assignee: Novartis AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • Methods of treating psoriasis using IL-17 antibody
    Patent number: 9717791
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: August 1, 2017
    Assignee: Novartis AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander